

IMP RTANT

Horizon Project IMPORTANT

IMPlimenting geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs

Research and Innovation Action
HORIZON-MISS-2020-CANCER-01
GA 101104589

Duration: 60 months
Start date: 01/05/2023

Deliverable ID.:	D3.2
Deliverable title:	Technical setup of systems and components for IMPORTANT clinical study
Planned delivery date:	31/10/2023
Actual delivery date:	30/10/2023
Deliverable leader:	CARE
Contributing partners:	
Dissemination Level:	V PU = Public
	CO = Confidential
	CI = Classified



This project has received funding from the European Union's Horizon Europe research and innovation program under grant agreement No 101104589.
This deliverable reflects only the author's view and the Commission is not responsible for any use that may be made of the information it contains.



Project Partners

Num.	Partner Name	Short Name	Country
1 (C)	OREBRO LANS LANDSTING	ORB	SE
2	PANEPISTIMI PATRON	UPAT	GR
3	CARE ACROSS LTD	CARE	UK
4	UNIVERSITA DEGLI STUDI DI FIRENZE	UNIFI	IT
5	AZIENDAUNITA SANITARIA LOCALE TOSCANA CENTRO	LHUTC	IT
6	HELSINGIN JA UUDENMAAN SAIRAANHOITOPPIIRIN	HUS	FI
7	INSTITUTE FOR MEDICAL TECHNOLOGY ASSESSMENT BV	IMTA	NL
8	SECURITY LABS CONSULTING LIMITED	SLC	IE
9	Circular Economy Foundation	CEF	BE
10	UNIVERSIDAD NACIONAL DE EDUCACION A DISTANCIA	UNED	ES
11	Elliniki Sinergazomeni Ogekologiki Omada	HECOG	GR
12	AKERSHUS UNIVERSITETSSYKEHUS HF	AHUS	NO
13	REGION UPPSALA	RUL	SE
14	FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA	FCRB	ES
15	HOSPITAL CLINIC DE BARCELONA	HCB	ES
16	FACHHOCHSCHULE NORDWESTSCHWEIZ	FHNW	CH
17	Phaze Clinical Research & Pharma Consulting S.A.	PHAZE	GR
18	Bröstcancerförbundet	BCF	SE
19	EUNOMIA LIMITED	EUNL	IE
20	Örebro university	ORU	SE

Project Coordinator: Dr Antonis Valachis - Örebro Läns Landsting (ORB)



List of Authors

Name(s)	Partner
Thanos Kosmidis	CARE

The list of authors reflects the major contributors to the activity described in the document. The list of authors does not imply any claim of ownership of the Intellectual Properties described in this document. The authors and the publishers make no expressed or implied warranty of any kind and assume no responsibilities for errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of the use of the information contained in this document.



Revision History

Date	Ver.	Author(s)	Summary of main changes
30/9/2023	0.1	Thanos Kosmidis	Initial layout
13/10/2023	0.5	Thanos Kosmidis	Additional diagrams
25/10/2023	0.9	Thanos Kosmidis	Final draft



Executive Summary

Deliverable D3.2 is of the type “DEM – Demonstrator, pilot, prototype”, and reflects the work being done for the systems and components involved in the IMPORTANT Clinical Study.

As such, the present document acts solely as an appendix to the above, providing reference to systems, flows and use cases. It is not meant to capture the complete or final state of the solution.

1. User/Stakeholder Actions and Responsibilities

As indicated in D2.2, there are several actions being considered for the design and implementation of the systems and processes. The below diagrams outline those key actions, as reference and supplementary material to assist with the understanding of the corresponding components.

1.1 Data Capture phase




Figure 1: Actions and Responsibilities of Stakeholders in Data Capture phase

1.2 Data Analysis & Cleaning phase




Figure 2: Actions & Responsibilities of Stakeholders in Data Analysis and Cleansing phase

1.3 Publishing Results phase




Figure 3: Actions and Responsibilities of Stakeholders in Publishing Results phase

2. Resulting Phases and Processes

Although the complexities of a Decentralised Clinical Trial cannot be easily captured in a diagram, such visualisations are important aids in communicating a common understanding of the architecture. Moreover, it is a key asset for facilitating any future updates that may need to be discussed, aligned and implemented.

In reviewing this diagram, it is important to keep in mind both the stakeholders (Patient, Research Team, CRO, Sponsor) and the possible timing of the corresponding processes.




Figure 4: IMPORTANT: key resulting Phases and Processes